Ocular toxoplasmosis during natalizumab treatment.
Servizio Cantonale di Neurologia-Ospedale Regionale, Lugano, Switzerlaand. chiarazecca@hotmail.com
Chiara
C
Zecca
Fabio
F
Nessi
Enos
E
Bernasconi
Claudio
C
Gobbi
D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D005123:Eye / Q000473:pathology; D006801:Humans; D007108:Immune Tolerance; D016867:Immunocompromised Host; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D009887:Ophthalmoscopy; D014122:Toxoplasma; D014126:Toxoplasmosis, Ocular / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab